Why the study?
Real-world site-level variability in health status outcomes for TMVr, and factors associated with this variability, are unknown.
What factors explain site-level variability in 30-day health status outcomes after TMVr in patients with mitral valve regurgitation?
What factors explain site-level variability in 30-day health status outcomes after TMVr in patients with mitral valve regurgitation?
Patient baseline health status is the primary driver of site-level variability in 30-day health status benefits following TMVr, highlighting the critical role of patient selection.
Answers are grounded in this paper and cite their sources.
Supports prioritizing baseline health status for TMVr selection; leaves open unmeasured site factors in outcome variability.
BACKGROUND: Clinical trials have demonstrated health status benefit of transcatheter mitral valve repair (TMVr) with MitraClip in patients with mitral valve regurgitation. Real-world site-level variability in health status outcomes for TMVr, and factors associated with this variability, are unknown. METHODS: ) explained by sequentially adding these variables to the model was quantified. RESULTS: =25%) with <1% of the variability explained by patient and procedural characteristics, and annual site volume. CONCLUSIONS: There is moderate variation across sites in their patients' achievement of health status benefits from TMVr, with patient's baseline health status accounting for the largest proportion of this variation. This underscores the importance of patient selection in supporting more consistent health status benefit from TMVr.
No takes yet. Share an insight, caveat, or question.
Malik et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: